Information with regards to Melanoma

The request was partially successful.

Dear St George's University Hospitals NHS Foundation Trust,

I would like to please request the following information:

The purpose of these questions is to understand the variability of treatment within your trust and in context to the rest of the country.

Q1. In the past 3 months (or the latest 3 months data you have available), how many melanoma patients were treated with:
• Bevacizumab (Avastin)
• Dacarbazine (DTIC)
• Trametinib (Mekinist)
• Dabrafenib (Tafinlar)
• Ipilimumab (Yervoy)
• Vemurafenib (Zelboraf)
• Nivolumab (Opdivo)
• Nivolumab + Ipilimumab (Opdivo + Yervoy)
• Pembrolizumab (Keytruda)
• Vemurafenib + cobimetinib (Zelboraf + Cotellic)
• Dabrafenib + Trametinib (Tafinlar + Mekinist)
• Braftovi (encorafenib) in combination with Mektovi (binimetinib) for BRAF V600 patients
• Other active systemic anti-cancer therapy [please state]
• Palliative care only

Q2. In the past 3 months (or the latest 3 months data you have available), how many metastatic melanoma patients were treated with the following:
• Ipilimumab
• Ipilimumab AND Nivolumab
• Nivolumab
• Pembrolizumab
• Dabrafenib AND Trametinib
• Any Other Targeted Therapy (Dabrafenib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
• Other active systemic anti-cancer therapy
• Palliative care only

Thank you for answering these questions.

Yours faithfully,

Ed Fryer

stgeorges@infreemation.co.uk, St George's University Hospitals NHS Foundation Trust

St Georges University Hospitals NHS Foundation Trust

 

 

 

Dear Correspondent,

Thank you for submitting your request for information, to St Georges
University NHS Foundation Trust.

If you have submitted a request under the Freedom of information Act
(FOIA) or the Environmental Information Regulations (EIR), we will respond
to your request within the statutory timescale of 20 working days which
excludes weekends, public holidays and bank holidays.

Please quote the above reference in all your correspondence with us.

Should you have any questions or queries about your request, please do not
hesitate to contact us by replying to this email and leaving the subject
line unchanged because, this ensures we have the right request your email
pertains to.

Your Sincerely,

Freedom of Information Team

St Georges University NHS Foundation Trust

stgeorges@infreemation.co.uk, St George's University Hospitals NHS Foundation Trust

St Georges University Hospitals NHS Foundation Trust

 

 

Dear Ed Fryer

Request FOI 2019

Further to your request to St Georges University Hospitals’ NHS Foundation
Trust (“The Trust”) which we received on 1 April 2022 I confirm that the
Trust has now considered your request under the Freedom of Information Act
2000 and the response is shown below;

Q1. In the past 3 months (or the latest 3 months data you have available),
how many melanoma patients were treated with:
• Bevacizumab (Avastin)                                    0
• Dacarbazine (DTIC)                                         0
• Trametinib (Mekinist)                                       0
• Dabrafenib (Tafinlar)                                        5 or fewer
• Ipilimumab (Yervoy)                                        5 or fewer
• Vemurafenib (Zelboraf)                                    0
• Nivolumab (Opdivo)                                        27
• Nivolumab + Ipilimumab (Opdivo + Yervoy)      5 or fewer
• Pembrolizumab (Keytruda)                               23
• Vemurafenib + cobimetinib (Zelboraf + Cotellic) 0
• Dabrafenib + Trametinib (Tafinlar + Mekinist)    5 or fewer
• Braftovi (encorafenib) in combination with Mektovi (binimetinib) for
BRAF V600 patients 7
• Other active systemic anti-cancer therapy [please state]  5 or
fewer          1
• Palliative care only      Not known

Q2. In the past 3 months (or the latest 3 months data you have available),
how many metastatic melanoma patients were treated with the following:
• Ipilimumab                              5 or fewer
• Ipilimumab AND Nivolumab     5 or fewer
• Nivolumab                              24
• Pembrolizumab                       6
• Dabrafenib AND Trametinib      5 or fewer
• Any Other Targeted Therapy (Dabrafenib /Encorafenib AND Binimetinib
/Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)     7
• Other active systemic anti-cancer therapy         0
• Palliative care only      Not known

Unfortunately we are not able to provide exact data where case numbers are
very small as this would contravene the data protection principles under
s40(2) of the Freedom of Information Act 2000. This is to avoid the risk
that individuals could be inferred or derived using information from other
sources .

The information supplied is protected by the Copyright, Designs and
Patents Act 1988. You are free to use it for your own purposes, including
any non-commercial research you are doing and for the purpose of news
reporting. Any other re-use, for example commercial publication, would
require the permission of the copyright holder.

The Trust publishes Access to Information requests and responses on its
online Disclosure Log. Only requests deemed to be in the public interest
will be included and any request included within this log will not
redacted accordingly.

To view the Trust's Disclosure Log, please copy and paste the following
details into an internet browser:

https://www.stgeorges.nhs.uk/about/foi/t...

If you have any queries about this email please do not hesitate to contact
us, quoting the reference number listed at the top of this letter in all
your correspondence.

If you are unhappy with our response to your request and wish to make a
complaint please write to us.

In the event you are have further queries following any such Internal
Review processes, you can contact the Information Commissioner's Office
at.

 

Information Commissioner
Helpline: 0303 123 1113
Wycliffe House 01625 545 745
 
Water Lane [1][email address]
Email:
Wilmslow [2]www.ico.org.uk
Website:
Cheshire SK9 5AF

 

Yours sincerely

Freedom of Information Team

St George's University Hospitals NHS Foundation Trust

References

Visible links
1. mailto:[email address]
2. http://www.ico.org.uk/